ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 05/27/24

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

- ARO-RAGE reduced serum sRAGE by up to 88% in patients with asthma - Additional promising results presented on two preclinical stage programs targeting thymic stromal lymphopoietin (TSLP) and influenza A viruses Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new ...

2024-05-17 10:44:05 ET Summary The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments. Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025. The...

2024-05-14 07:08:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 ...

2024-05-13 10:30:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ARWR on May 13, 2024 08:34AM ET. The previous analyst recommendation was Equal-Weight. ARWR was trading at $22.39 at issue of the analyst recommendation. The overall analyst consensus : ...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

2024-05-09 21:23:07 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Conference Call May 09, 2024, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chi...

2024-05-09 16:01:55 ET More on Arrowhead Pharmaceuticals Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade) Arrowhead Pharmaceuticals Q2 2024 Earnings Preview Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma See...

- Conference Call and Webcast Today, May 9, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discu...